SURPASS-2: The Trial That Changed the Competitive Landscape
The SURPASS-2 trial is arguably the most consequential study in the tirzepatide clinical program. Published in the New England Journal of Medicine in August 2021 by Frías et al., this was the first randomized, head-to-head comparison of tirzepatide against semaglutide — the reigning champion of GLP-1 receptor agonists. The results unequivocally demonstrated tirzepatide's superiority across both glycemic and weight endpoints [1].
Study Design
SURPASS-2 was a 40-week, open-label, randomized Phase 3 trial conducted at 128 sites across 13 countries. The study enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin alone (≥1,500 mg/day for ≥3 months).
Randomization:
- Tirzepatide 5 mg (n=470)
- Tirzepatide 10 mg (n=469)
- Tirzepatide 15 mg (n=470)
- Semaglutide 1 mg (n=469)
The choice of semaglutide 1 mg (Ozempic) as the comparator was significant — at the time of trial design, this was the highest approved dose of semaglutide for type 2 diabetes and was considered the gold standard for injectable GLP-1 receptor agonist therapy.
Head-to-Head Glycemic Results
Tirzepatide demonstrated superiority at all three doses:
Mean HbA1c Change from Baseline (~8.3%):
- Tirzepatide 5 mg: -2.01%
- Tirzepatide 10 mg: -2.24%
- Tirzepatide 15 mg: -2.30%
- Semaglutide 1 mg: -1.86%
Treatment Difference vs. Semaglutide:
- 5 mg: -0.15% (P=0.02 for non-inferiority and superiority)
- 10 mg: -0.39% (P<0.001)
- 15 mg: -0.45% (P<0.001)
HbA1c Target Achievement (<7.0%):
- Tirzepatide 5 mg: 82%
- Tirzepatide 10 mg: 86%
- Tirzepatide 15 mg: 86%
- Semaglutide 1 mg: 79%
HbA1c <5.7% (Normal Range):
- Tirzepatide 5 mg: 27%
- Tirzepatide 10 mg: 40%
- Tirzepatide 15 mg: 46%
- Semaglutide 1 mg: 19%
Nearly half of patients on tirzepatide 15 mg achieved a completely normal HbA1c — more than double the rate with semaglutide [1].
Head-to-Head Weight Loss Results
The weight loss comparison was equally decisive:
Mean Body Weight Change:
- Tirzepatide 5 mg: -7.6 kg (-7.8%)
- Tirzepatide 10 mg: -9.3 kg (-9.6%)
- Tirzepatide 15 mg: -11.2 kg (-11.6%)
- Semaglutide 1 mg: -5.7 kg (-5.9%)
Treatment Difference vs. Semaglutide:
- 5 mg: -1.9 kg (P=0.009)
- 10 mg: -3.6 kg (P<0.001)
- 15 mg: -5.5 kg (P<0.001)
At the highest dose, tirzepatide produced nearly double the weight loss of semaglutide 1 mg. Even the lowest tirzepatide dose (5 mg) produced statistically significantly more weight loss than semaglutide [1].
Why Does Tirzepatide Outperform Semaglutide?
The superiority of tirzepatide is attributed to its dual mechanism:
The GIP Component:
- GIP receptor activation enhances fat oxidation and energy expenditure
- GIP signaling in the brain may provide additional appetite suppression beyond GLP-1 alone
- GIP improves adipose tissue function and insulin sensitivity
- The combination creates synergistic metabolic effects
Pharmacological Considerations:
- Tirzepatide has a longer half-life (~5 days) than semaglutide (~7 days), but its dual-receptor engagement provides broader metabolic coverage
- The GIP component may help counteract some of the GI side effects of GLP-1 agonism
- Tirzepatide's biased agonism at the GLP-1 receptor may contribute to its distinct pharmacological profile [2].
Safety Comparison
The safety profiles were broadly similar:
Gastrointestinal Events:
- Nausea: 17-22% (tirzepatide) vs. 18% (semaglutide)
- Diarrhea: 13-16% vs. 12%
- Vomiting: 6-10% vs. 8%
- Decreased appetite: 6-10% vs. 5%
Hypoglycemia (<54 mg/dL):
- Tirzepatide: 0.4-0.6%
- Semaglutide: 0.2%
Discontinuation due to adverse events:
- Tirzepatide: 3-7%
- Semaglutide: 4%
Notably, despite producing significantly greater weight loss and glucose lowering, tirzepatide did not have meaningfully higher rates of adverse events compared to semaglutide [1].
The Dosing Caveat
An important consideration in interpreting SURPASS-2 is the semaglutide dose used. The trial compared tirzepatide against semaglutide 1 mg (Ozempic), which is the diabetes dose. The higher 2.4 mg dose (Wegovy), approved for obesity, was not available as a comparator at the time of trial design.
This means the comparison was not against semaglutide's maximum potential. However, even accounting for this, the magnitude of tirzepatide's advantage — particularly at the 10 mg and 15 mg doses — suggests genuine superiority of the dual-agonist mechanism. This was later confirmed in the SURMOUNT-5 trial, which compared tirzepatide directly against semaglutide 2.4 mg for obesity [3].
Clinical Impact
SURPASS-2 had profound implications:
- Regulatory pathway: Provided key evidence for Mounjaro's FDA approval for type 2 diabetes in May 2022
- Treatment algorithms: Positioned tirzepatide as a preferred option over semaglutide for patients needing maximum glycemic control and weight loss
- Market dynamics: Created intense competition between Eli Lilly and Novo Nordisk in the GLP-1 space
- Clinical practice: Gave physicians a clear rationale for choosing tirzepatide when both glycemic control and weight loss are priorities
References
-
Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503-515. PubMed: 34170647
-
Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metabolism. 2022;34(8):1234-1247. PubMed: 35985340
-
Aronne LJ, Sattar N, Horn DB, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." New England Journal of Medicine. 2025. PubMed: 40353578
